Lipigon Pharmaceuticals AB (LPGO) — Strategic Asset Allocation Index
Lipigon Pharmaceuticals AB (LPGO) has a Strategic Asset Allocation Index of 0.2% as of June 2023. Strategic assets (PP&E of Skr61.00K plus long-term investments of Skr-) total Skr61.00K, measured against net assets of Skr27.59 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Lipigon Pharmaceuticals AB balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Lipigon Pharmaceuticals AB Strategic Asset Allocation Index (2021–2022)
This chart shows how Lipigon Pharmaceuticals AB's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 0.2%, representing strategic assets of Skr61.00K against net assets of Skr27.59 Million SEK. For live market cap and overall valuation, see LPGO market cap.
Annual Strategic Asset Allocation Index for Lipigon Pharmaceuticals AB (2021–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Lipigon Pharmaceuticals AB from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Lipigon Pharmaceuticals AB net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (SEK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.9% | Skr72.00K | Skr72.00K | Skr- | Skr3.87 Million | ▲ +1.4 pp |
| 2021 | 0.4% | Skr96.00K | Skr96.00K | Skr- | Skr22.96 Million | — |